Percentage of Myeloid Dendritic Cells in Peripheral Venous Blood Is Negatively Related to Incidence of Graves' Orbitopathy

Overview

Journal Mediators Inflamm

Publisher Wiley

Specialties Biochemistry
Pathology

Date 2021 Feb 12

PMID 33574732

Citations 4

Authors

Katarzyna Wojciechowska-Durczynska

Katarzyna Wieczorek-Szukala

Borys Stefanski

Arkadiusz Zygmunt

Jan Stepniak

Malgorzata Karbownik-Lewinska

Andrzej Lewinski

Affiliations

Soon will be listed here.

Abstract

The aim of the study was to evaluate the distribution of blood dendritic cells (DCs) in patients with Graves' orbitopathy (GO) and to assess the influence of methylprednisolone therapy on subsets of peripheral blood mononuclear cells (PBMCs). Peripheral blood DC subsets were analyzed by flow cytometry in patients with active GO ( = 17), inactive GO ( = 8), and Graves' disease (GD) without GO ( = 8) and controls ( = 15); additionally, in patients with active GO ( = 17), analyses were done at three time points, i.e., before methylprednisolone treatment and after 6 weeks and after 12 weeks of the treatment. Percentage of myeloid DCs (mDCs) in PBMC fraction was significantly lower in patients with both active and inactive GO, compared to patients with GD without GO and controls ( < 0.05). In addition, mDCs were also documented to be an independent factor negatively associated with GO, however without essential differences between active and inactive phases. On the other hand, we did not observe any changes in the percentage of DCs after methylprednisolone therapy ( > 0.05). In the present study, we have succeeded to firstly demonstrate-according to our knowledge-that blood mDCs are negatively related to GO incidence.

Citing Articles

The Increased FCRL mRNA Expression in Patients with Graves' Disease Is Associated with Hyperthyroidism (But Not with Positive Thyroid Antibodies).

Wojciechowska-Durczynska K, Stepniak J, Lewinski A, Karbownik-Lewinska M J Clin Med. 2024; 13(17).

PMID: 39274506 PMC: 11396638. DOI: 10.3390/jcm13175289.

Plasma exosomes from patients with active thyroid-associated orbitopathy induce inflammation and fibrosis in orbital fibroblasts.

Wei L, Huang Q, Tu Y, Song S, Zhang X, Yu B J Transl Med. 2024; 22(1):546.

PMID: 38849907 PMC: 11157872. DOI: 10.1186/s12967-024-05263-y.

Single-cell BCR and transcriptome analysis reveals peripheral immune signatures in patients with thyroid-associated ophthalmopathy.

Li Q, An N, Liu C, Ding Y, Yang C, Ma X Aging (Albany NY). 2024; 16(9):8217-8245.

PMID: 38728262 PMC: 11132005. DOI: 10.18632/aging.205814.

Predictive markers for anti-inflammatory treatment response in thyroid eye disease.

Zhang H, Fan J, Qu J, Han Q, Zhou H, Song X Front Endocrinol (Lausanne). 2023; 14:1292519.

PMID: 38111706 PMC: 10726127. DOI: 10.3389/fendo.2023.1292519.

References

Smith T, Kahaly G, Ezra D, Fleming J, Dailey R, Tang R . Teprotumumab for Thyroid-Associated Ophthalmopathy. N Engl J Med. 2017; 376(18):1748-1761. PMC: 5718164. DOI: 10.1056/NEJMoa1614949. View

Dedecjus M, Stasiolek M, Brzezinski J, Selmaj K, Lewinski A . Thyroid hormones influence human dendritic cells' phenotype, function, and subsets distribution. Thyroid. 2010; 21(5):533-40. DOI: 10.1089/thy.2010.0183. View

Leskela S, Rodriguez-Munoz A, de la Fuente H, Figueroa-Vega N, Bonay P, Martin P . Plasmacytoid dendritic cells in patients with autoimmune thyroid disease. J Clin Endocrinol Metab. 2013; 98(7):2822-33. DOI: 10.1210/jc.2013-1273. View

Fang S, Huang Y, Wang N, Zhang S, Zhong S, Li Y . Insights Into Local Orbital Immunity: Evidence for the Involvement of the Th17 Cell Pathway in Thyroid-Associated Ophthalmopathy. J Clin Endocrinol Metab. 2018; 104(5):1697-1711. DOI: 10.1210/jc.2018-01626. View

Passlick B, Flieger D . Identification and characterization of a novel monocyte subpopulation in human peripheral blood. Blood. 1989; 74(7):2527-34. View

Eckstein A, Quadbeck B, Tews S, Mann K, Kruger C, Mohr C . Thyroid associated ophthalmopathy: evidence for CD4(+) gammadelta T cells; de novo differentiation of RFD7(+) macrophages, but not of RFD1(+) dendritic cells; and loss of gammadelta and alphabeta T cell receptor expression. Br J Ophthalmol. 2004; 88(6):803-8. PMC: 1772193. DOI: 10.1136/bjo.2003.035915. View

Rissoan M, Soumelis V, Kadowaki N, Grouard G, Briere F, de Waal Malefyt R . Reciprocal control of T helper cell and dendritic cell differentiation. Science. 1999; 283(5405):1183-6. DOI: 10.1126/science.283.5405.1183. View

Passlick B, Flieger D . The monoclonal antimonocyte antibody My4 stains B lymphocytes and two distinct monocyte subsets in human peripheral blood. Hybridoma. 1988; 7(6):521-7. DOI: 10.1089/hyb.1988.7.521. View

Mao C, Wang S, Xiao Y, Xu J, Jiang Q, Jin M . Impairment of regulatory capacity of CD4+CD25+ regulatory T cells mediated by dendritic cell polarization and hyperthyroidism in Graves' disease. J Immunol. 2011; 186(8):4734-43. DOI: 10.4049/jimmunol.0904135. View

10.

Moseman E, Liang X, Dawson A, Panoskaltsis-Mortari A, Krieg A, Liu Y . Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells. J Immunol. 2004; 173(7):4433-42. DOI: 10.4049/jimmunol.173.7.4433. View

11.

Hassan I, Brendel C, Zielke A, Burchert A, Danila R . Immune regulatory plasmacytoid dendritic cells selectively accumulate in perithyroidal lymph nodes of patients with Graves disease: implications for the understanding of autoimmunity. Rev Med Chir Soc Med Nat Iasi. 2014; 117(1):46-51. View

12.

Agrawal S, Gupta S, Agrawal A . Human dendritic cells activated via dectin-1 are efficient at priming Th17, cytotoxic CD8 T and B cell responses. PLoS One. 2010; 5(10):e13418. PMC: 2956651. DOI: 10.1371/journal.pone.0013418. View

13.

Ito T, Yang M, Wang Y, Lande R, Gregorio J, Perng O . Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand. J Exp Med. 2007; 204(1):105-15. PMC: 2118437. DOI: 10.1084/jem.20061660. View

14.

Purnamasari D, Soewondo P, Djauzi S . Dendritic cells in Graves' disease. Acta Med Indones. 2015; 47(1):61-9. View